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Abstract 
Aim: To evaluate the relation between different serum lipid fractions and other known 
barriers to attain the HbA1c ≤ 7.0% (53 mmol/mol) target.  
Methods: Data on 2719 patients with type 2 diabetes were collected from the five waves of 
the International Diabetes Mellitus Practice Study implemented in Argentina (2006 to 2012) 
including: demographic/socioeconomic profile, clinical, metabolic (HbA1c and serum lipids) 
data, and treatment type; also, percentage of treatment goal attainment. Descriptive statistical 
analyses included ANOVA, Chi2 test, and Fisher’s exact test; univariate and multivariate 
logistic regression analyses, that identified predictive factors for HbA1c ≤7% (53 mmol/mol).  
Results: The average age was 63 years, primary/secondary education, health insurance, 10-
year type 2 diabetes duration, most associated with cardiovascular risk factors and some 
microvascular/macrovascular complications; 94.5% received antihyperglycemic drugs. 
Percentage of people on target: HbA1c 51.2%, blood pressure 23.5%, total cholesterol 62.6%, 
LDL-cholesterol 38.9% and triglycerides 61.1%. HbA1c on target depended markedly on 
treatment type: more of those treated with lifestyle changes and significantly fewer of those 
receiving insulin. Only 4.1% had all parameters simultaneously on target. Multivariate 
logistic regression analyses showed that achieving HbA1c≤7.0% (53 mmol/mol) was 
associated with higher educational level, shorter diabetes duration, and having reached goals 
for LDL-cholesterol and triglycerides, whereas opposite results were obtained with insulin 
treatment and longer diabetes duration.   
Conclusions: High LDL-cholesterol and triglycerides levels simultaneously potentiate 
development/progression of chronic complications, exerting this effect in the long term by 
decreasing β-cell mass/function, thereby making it more difficult to reach HbA1c values able 
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1. Introduction 
Type 2 diabetes is a chronic disease frequently associated with other cardiovascular risk 
factors (CVRF) that facilitate development/progression of chronic complications and increase 
treatment costs (1), thereby becoming a heavy burden on patients and the health budget (2,3).  
This disease is characterized by sustained hyperglycemia caused by progressive failure of β-cell 
secretion failing to cope with increased demand for hormone by peripheral tissues (insulin 
deficiency + insulin resistance) (4-7). This deficient response results from progressive 
impairment of β-cell mass and function (8-10); consequently, at some stage of the disease, 
insulin administration may be necessary to attain recommended HbA1c target values, which 
requires overcoming physicians’ and patients’ barriers (7,11,12). Time-course changes in 
treatment type leads to a different percentage of people with HbA1c on target: in a previous 
International Diabetes Mellitus Practice Study report (IDMPS), we showed that for people with 
type 2 diabetes, short disease duration and use of few oral glucose-lowering drugs (OGLDs) 
were predictive factors of attaining target HbA1c values in all regions studied (13). 
Available evidence also shows that diabetes is an independent risk factor for developing 
cardiovascular risk; with such events being the most common cause of death in type 2 diabetes 
(14,15). However, multifactorial care of people with type 2 diabetes (simultaneous treatment of 
hyperglycemia, hypertension, and dyslipidemia) effectively reduced rates of death and 
cardiovascular disorders (16). Also, this multifactorial approach could have additional 
advantages: since dyslipidemia exerts a direct deleterious effect on β-cell mass/function (17), 
its control might not only prevent occlusive atherosclerosis, but could also prolong β-cell half-
life and consequently, improve chances of reaching HbA1c goal values.  
We now provide additional evidence to support the latter assumption by evaluating the relation 
between attainment of HbA1c ≤ 7.0% (53mmol/mol) values and of different serum lipid 
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fractions, as well as other known barriers to attain this goal by analyzing data from the five 
waves of the IDMPS implemented in Argentina between 2006 and 2012. 
 
2. Methods  
2.1. Study design 
IDMPS is an international, multicenter, prospective, observational study on patients with type 
1 and type 2 diabetes. This survey is designed following STROBE guidelines as described 
elsewhere (13,18). Briefly, IDMPS is composed of 5 cross-sectional registries (operationally 
called ‘‘waves’’) over a 5-year period to assess changing practices in the management of 
people with diabetes. Each wave consists of two phases: a 2-week cross-sectional registry and 
a 9-month longitudinal survey. A 3-month interval separates the end of the longitudinal 
survey and the start of the next wave. Only cross-sectional registry data from Argentina are 
analyzed in the present report. 
2.2. Data collection and outcome measures  
Data were collected on case report forms recording demographic and socioeconomic profile, 
medical history, medications, glycemic control, blood pressure and lipid status, self-care, 
access to patient education, follow-up mode, work absenteeism, and hospitalization. Outcome 
measurement included attainment of treatment goals defined as HbA1c ≤7% (53 mmol/mol), 
blood pressure ≤130/80 mmHg, and LDL cholesterol ≤100 mg/dl (19).  
2.3. Sample size estimation and selection of physicians 
The number of subjects to be recruited in each participating country was determined on a 
country basis. Based on the assumption that insulin is the least prescribed therapy, the sample 
was determined in order to establish the frequency of insulin-treated patients (13,18). 
Therefore, physicians with experience on the initiation and titration of insulin therapy were 
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invited to participate. A total of 210 Argentinian physicians participated in the 5 waves (2719 
patients with type 2 diabetes).  
2.4. Study implementation 
A steering committee advised the project team on the study design and registry structure, 
monitored study progress, reviewed and validated all study-related documents, and proposed 
and approved decisions on protocol amendments, analyses, and publications. The study was 
coordinated by Sanofi-Aventis Intercontinental. In each country, the study was advocated by 
a leading diabetologist who compiled and endorsed the list of investigators. The latter were 
assisted by local Sanofi-Aventis staff in collecting relevant information including clinical and 
laboratory parameters. Ethics approval was obtained from institutional boards from each 
country. All participants provided their written informed consent.  
2.5. Statistical analysis 
Statistical analyses were conducted with the Statistical Package for Social Sciences version 
15 (SPSS Inc., Chicago, IL, USA). Descriptive Analysis, ANOVA, Chi2 Test, and Fisher’s 
Exact Test were used as appropriate. Univariate and multivariate logistic regression analyses 
were run to identify predictive factors for HbA1c ≤7% (53 mmol/mol). Potential predictive 
factors included gender, age, diabetes duration, education level, health insurance, Body Mass 
Index (BMI), blood pressure, lipid profile (Total Cholesterol, LDL Cholesterol, and TG), and 




Most of our study population was urban (93.9%), had a primary/secondary education, 
declared combined social security/prepaid health insurance, had some degree of 
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microvascular/macrovascular complications and were treated with different 
antihyperglycemic drugs (94.4%). Regarding treatments, most patients were treated with 
OGLDs (60.8%), while insulin treatment (alone [12.5%] or combined with OGLD [21.1%]) 
represented 33.6% (Table 1). 
Their clinical-metabolic characteristics showed an average of 63 years of age, of 10-year 
duration of type 2 diabetes; most having associated CVRFs, specifically, overweight/obesity 
(87.5%), hypertension (73%) and dyslipidemia (70.3%) (Table 1). Average values for the 
parameters recorded showed blood pressure within target values recommended by 
ADA/EASD guidelines (23), moderate increase in fasting blood sugar, HbA1c levels close to 
those recommended by guidelines, and uneven control of their serum lipid profile (Table 1). 
In fact, whereas total cholesterol, HDL-c and TG levels were within control levels, those of 
LDL-c were above treatment goals (Table 1). 
Despite this acceptable average value profile, a different picture emerged when it was 
considered the percentage of people on target for each parameter, i.e. values able to prevent 
development/progression of chronic complications (Table 1): for HbA1c it was 51.2%, for 
blood pressure 23.5%, for total cholesterol 62.6%, for LDL-cholesterol 38.9%, and for TG 
61.1%. It has to be stressed that the percentage of people with HbA1c on target varied 
markedly depending on treatment type: higher in the group of people treated with lifestyle 
changes and significantly lower in those receiving insulin (Figure 1). However, when we 
measured the percentage of people having their HbA1c, blood pressure and complete lipid 
profile simultaneously on target, we found that only 4.1% attained that goal.   
Regarding our main objective –to verify the negative influence of dyslipidemia on attainment 
of the HbA1c goal- when we tracked the population according to their Hba1c levels ≤ 7.0% ( 
53 mmol/mol), we found that those who attained HbA1c target values exhibited significantly 
lower levels of lipid fractions (Table 2).  
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The results of multivariate logistic regression analyses presented in Figure 2, show that for 
people with type 2 diabetes, achieving HbA1c≤7.0% (53 mmol/mol) was a positively 
association with a higher educational level (OR: 1.399, 95% CI: 1.107 - 1.767), and with 
having reached the goal for LDL-cholesterol (OR: 1.344, 95% CI: 1.091 - 1.656) and TG 
(OR: 1.854, 95% CI: 1.501 - 2.290), whereas it was negatively associated with insulin 
treatment (OR: 0.296, 95% CI: 0.186 - 0.470) and diabetes duration (either OR: 0.762, 95% 
CI 0.588 -0.987 or OR: 0.541, 95% CI 0.420 – 0.696).   
 
4. Discussion    
Chronic type 2 diabetes complications result in high morbidity, mortality, and socio-
economic costs, which can be significantly reduced by control of hyperglycemia and 
associated CVRF - unfortunately achieved infrequently (2, 20-22). In our study, 
approximately 50% of the population was on the target values recommended by ADA 
standards for HbA1c and other CVRFs (23).  
On the other hand, the intensive multifactorial approach to treat these people has been shown 
to be an efficient and cost-effective way to prevent development and progression of these 
complications (16, 24, 25). However, in our country, only about 4% of the population attain 
this multifactorial goal. 
For HbA1c the target is ≤ 7.0%; the attainment of this value depends on many factors: in our 
study, treatment type was significantly associated with different percentages of people on 
target: a higher percentage was attributable to healthy lifestyle and a lower percentage to 
insulin treatment. Similar polarizations were also found by other authors (26). In a previous 
IDMPS report performed worldwide, we found that people with short duration type 2 
diabetes and use of few OGLDs were predictive factors of attaining HbA1c at target values in 
all regions studied (13). Similarly, the United Kingdom Prospective Diabetes Study (14), 
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which examined the time-course of islet dysfunction in patients with type 2 diabetes, showed 
that β-cell function - estimated by HOMA index - underwent progressive deterioration during 
the first 6 years of observation in patients without insulin therapy (27). Comparable data were 
reported by De Pablo et al: using a logistic model, they found that disease duration was 
predictive of glycemic control (longer was associated with higher frequency of poor glycemic 
control (OR = 1.033) and stable insulin treatment (OR = 4.054)) (28). These data suggest that 
early diagnosis may increase the likelihood of attaining glycemic targets, probably because 
people with type 2 diabetes show progressive deterioration of both β-cell mass and function 
(7,8,10). Accordingly, we may reasonably assume that remnant functional β-cell mass 
efficiently controls glucose homeostasis at an earlier stage of the disease, whereas later on 
this control depends on the physician-patient couple’s abilities/commitment. However, other 
factors may also participate in triggering the impaired mechanism: the multiple variable 
analysis performed in our study demonstrated that educational level, disease duration, blood 
pressure, total cholesterol, LDL-cholesterol and TG levels as well as treatment type (except 
OGLDs), also significantly affect attainment of HbA1c ≤ 7.0% (53 mmmol/mol) (Figure 2). 
Reciprocally, HbA1c is not only a reliable biomarker of glycemic control but also may be a 
good predictor of serum lipid profile in people with type 2 diabetes: those with HbA1c ≤ 6%–
9% (42-75 mmol/mol) and >9% (75 mmol/mol) tend to have moderate and severe 
dyslipidemia, respectively (29), even though further studies need to be driven to assess this. 
The principal aim of our study is to gain deep insight into the analysis of dyslipidemia’s role 
in attainment of target HbA1c values. 
People with normal glucose tolerance (NGT) and dyslipidemia characterized by abnormal 
high TG and low HDL-c have also been shown to have impaired insulin sensitivity and β-cell 
function: levels of these lipid fractions correlated with insulin resistance (IR), while they 
were negatively correlated with pancreatic β-cell response to IR (30). The HOMA-IR score is 
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a useful but costly indicator of IR and therefore frequently inaccessible for general purposes; 
for this reason, the TG/HDL-cholesterol ratio has been proposed for use as a simple IR 
marker (31, 32); with some ethnic restrictions, it might be inversely related to β-cell function 
(33). The cut-off value for this TG/HDL-cholesterol ratio was validated in our country as 
>3.5 and >2.5 for men and women, respectively (34). Following this reasoning, in a 
longitudinal assessment of the temporal relations between serum lipids and IR using cross-
lagged path analysis models, Han et al found that abnormally high levels of TG and low 
HDL-cholesterol probably precede those of peripheral IR (35). They also showed a 
significant causal mediating effect of 2-h insulin on the unidirectional relation running from 
blood lipids to IR. These findings provide more evidence for effective IR prevention by 
improving dyslipidemia. 
Further, LDL-cholesterol can decrease maximal glucose-stimulated insulin secretion (GSIS) 
already in the normal range (3.1 mmol/L) in isolated human and murine islets (17). These 
results were confirmed and extended by in vivo conditions: mice with hypercholesterolemia 
induced by feeding a cholesterol-rich Western type diet showed increased cholesterol content 
in their β-cells associated with reduced GSIS and hyperglycemia; while LDL-cholesterol 
decreased the proliferation of primary β-cells in mouse or human islets (17). Identification of 
plasma lipoprotein receptor in pancreatic β cells involved in their binding/processing, as well 
as the report that LDL-cholesterol particles reduce insulin mRNA levels and β-cell 
proliferation and also induce a dose-dependent increase in their apoptotic rate, support this 
assumption. Conversely, HDL-cholesterol particles antagonize the proapoptotic effect of 
LDL-cholesterol. The antagonistic effect of LDL-, HDL- and cholesterol on regulation of β-
cell function and survival as well as on target tissue insulin sensitivity and consequently on 
type 2 diabetes development were reviewed by von Eckardstein and Siblera (36). These and 
other reports suggest that the deleterious effect of increased LDL-cholesterol on β-cell 
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function/mass could be potentiated by the simultaneous decrease in HDL-cholesterol 
concentration (17,37,38). 
Related to the relation between HbA1c and LDL-cholesterol levels and their impact on 
cardiovascular complications, a retrospective study among US veterans with type 2 diabetes 
concluded that simultaneous target achievement of these two metabolic indicators rather than 
each one separately was associated with lower risk of microvascular and macrovascular 
events, fewer hospitalization days and outpatient visits; thus resulting in better outcomes and 
lower resource consumption (39). 
Based on this evidence, we could conclude that dyslipidemia, particularly high LDL-
cholesterol and TG levels, not only may potentiate development/progression of chronic 
complications, but also could exert this effect in the long term by decreasing β-cell mass and 
function which making more difficult to reach HbA1c target values able to prevent this 
effect. Our data also show that these dual negative effects of dyslipidemia are not seriously 
considered by our physicians since an important percentage of people with high LDL-
cholesterol and TG levels were not treated or not treated specifically to bring them down to 
target values. 
We assume that, although consistent, our data have some weaknesses and must therefore be 
considered with caution: a) it is a retrospective data analysis; b) it is not a strict population 
study, since providers were mainly specialists, consequently not representative of large 
population health care quality. However, the latter factor is particularly alarming, since if 
serious failures were detected at this level, patient care at the primary care level must 
presumably be worse. 
Data obtained from our ongoing primary care level, showing the beneficial effects of 
education of physicians, nurses, and type 2 diabetes patients for attaining target values of 
HbA1c and serum lipids, as well as its cost-effective ratio (40), support the concept that 
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education is a reliable tool to modify the current impaired prescription/adherence and to 
optimize the quality of care and prevention of complications. 
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Figure 1. People with type 2 diabetes on Target (HbA1c ≤7% /<53 mmol/mol)) by Treatment 
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Figure 2. Multivariate Logistic Regression 
  
* Reference modality in underlined and italic text 
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Table 1. Characteristics of the study population 
Parameter Mean ± SD % N 
Male (%) - 51.8 1,376 
Age (years) 63.4 ± 11.1 - 2,716 





 Illiterate (%) 
 
1.0 27 
 Primary / Secondary (%) 
 
73.7 1,924 
 University or higher (%) 
 
25.3 662 




 Public (%) 
 
40.7 943 
 Private / Mixed (%) 
 
59.3 1,374 
BMI (kg/m2) 30.8 ± 5.6 - 2,709 
 Normal weight (18.5 ≤ BMI <25) (%) - 12.6 340 
 Overweight (25 ≤ BMI < 30) (%) - 38.0 1,029 
 Obesity (30 ≤ BMI < 35) (%) - 29.3 793 
 Morbid obesity (BMI ≥ 35) (%) - 20.2 546 
SBP (mmHg) 130.2 ± 15.0 - 2,701 
DBP (mmHg) 78.6 ± 9.7 - 2,702 
SBP<130 and DBP<80 (%) - 23.5 636 
FBG (mg/dl) 137.5 ± 49.0 - 2,621 
HbA1c (%) 7.3 ± 1.6 - 2,552 
HbA1c ≤ 7% (53 mmol/mol) - 51.2 1,306 
Total Cholesterol (mg/dl) 189.5 ± 38.7 - 2,516 
Total Cholesterol < 200mg/dl (%) - 62.6 1,576 
HDL-c (mg/dl) 49.5 ± 16.6 - 2,401 
LDL-c (mg/dl) 111.2 ± 33.6 - 2,323 
LDL-c < 100 mg/dl (%) - 38.9 911 
Triglycerides (mg/dl) 151.2 ± 83.4 - 2,493 
Triglycerides < 150 mg/dl (%) - 61.1 1,523 
Hypertension (%) - 73.0 1,976 
Dyslipemia (%) - 70.3 1,892 
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Micro- or macrovascular Complications (%)   43.9 1,119 
Treatment type    
 D&F (%)  5.6 144 
 OGLDs Only (%)  60.8 1,551 
 OGLDs and Insulin (%)  21.1 538 
 Insulin alone (%)  12.5 319 
 
SD: standard deviation. SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FBG: 
Fasting blood glucose; HDL-c: High density lipoprotein cholesterol; LDL-c: Low-density 
lipoprotein cholesterol; BMI: Body mass index. D&F: Diet and Physical Activity, OGLDs: 
Oral Glucose Lowering Drugs 
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Table 2. Dyslipidemia according to HbA1c level.  
Parameter 
HbA1c > 7%    
(53 mmol/mol 
HbA1c ≤ 7% 
(53 mol/mol) 
P-value 
Total Cholesterol (mg/dl) 193.3 ± 40.1 (1,167) 184.2 ± 36.3 (1,243) 0.000 
Total Cholesterol < 200 mg/dl (%) 59.2 (691) 68.1 (846) 0.000 
HDL-c (mg/dl) 49.2 ± 18.4 (1,110) 49.9 ± 14.6 (1,207) 0.341 
LDL-c (mg/dl) 114.5 ± 34.7 (1,071) 107.2 ± 31.7 (1,171) 0.000 
LDL-c < 100 mg/dl (%) 35.6 (384) 42.9 (507) 0.000 
Triglycerides (mg/dl )  162.6 ± 94.8 (1,154) 138.9 ± 67.7 (1,239) 0.000 
Triglycerides < 150 mg/dl (%) 55.5 (640) 67.2 (833) 0.005 
 
Values are mean ± standard deviation (SD). Number of cases in parentheses. 
HDL-c: High density lipoprotein cholesterol; LDL-c: Low-density lipoprotein cholesterol. 
 
 
